Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 3, 2012, Pages 356-363

  Aoyama, T ^a   Hirata, K ^a,b   Hirata, R ^c   Yamazaki, H ^c   Yamamoto, Y ^b   Hayashi, H ^a   Matsumoto, Y ^a  

^a NIHON UNIVERSITY   (Japan)

^b NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

^c SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

critically ill patients; fluconazole; fosfluconazole; modelling and simulation; pharmacokinetics; population pharmacokinetic analysis

Indexed keywords

FLUCONAZOLE; FOSFLUCONAZOLE; PRODRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; SYSTEMIC MYCOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; COMPUTER SIMULATION; FEMALE; FLUCONAZOLE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; INTENSIVE CARE; JAPAN; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; MYCOSES; PHOSPHORIC ACID ESTERS; PRODRUGS; YOUNG ADULT;

EID: 84861338082     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01297.x     Document Type: Article

References (33)

1. Bustamante C, (2005) Treatment of Candida infection: a view from the trenches! Current Opinion in Infectious Diseases, 18, 490-495.
2. Shiba K, Saito A, Miyahara T, (1989) Pharmacokinetic evaluation of fluconazole in healthy volunteers. Japanese Journal of Antibiotics, 42, 17-30.
3. Humphrey M, Jevons S, Tarbit M, (1985) Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrobial Agents and Chemotherapy, 28, 648-653.
4. Sobue S, Tan K, Layton G, Eve M, Sanderson J, (2004) Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers. British Journal of Clinical Pharmacology, 58, 20-25.
5. Wade K, Wu D, Kaufman D, et al. (2008) Population pharmacokinetics of fluconazole in young infants. Antimicrobial Agents and Chemotherapy, 52, 4043-4049.
6. Pai M, Turpin R, Garey K, (2007) Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrobial Agents and Chemotherapy, 51, 35-39.
7. Boucher B, Wood G, Swanson J, (2006) Pharmacokinetic changes in critical illness. Critical Care Clinics, 22, 255-271, vi.
8. Hirata K, Matsumoto Y, Kurokawa A, et al. (2003) Possibility of influence of midazolam sedation on the diagnosis of brain death: concentrations of active metabolites after cessation of midazolam. Yakugaku Zasshi, 123, 811-815.
9. Cota J, Burgess D, (2010) Antifungal dose adjustment in renal and hepatic dysfunction: pharmacokinetic and pharmacodynamic considerations. Current Fungal Infection Reports, 4, 120-128.
10. Tanigawara Y, Sato R, Morita K, Kaku M, Aikawa N, Shimizu K, (2006) Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 50, 3754-3762.
11. Katsube T, Yano Y, Wajima T, Yamano Y, Takano M, (2010) Pharmacokinetic/pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem. Journal of Pharmaceutical Sciences, 99, 2483-2491.
12. Herd D, Anderson B, Holford N, (2007) Modeling the norketamine metabolite in children and the implications for analgesia. Paediatric Anaesthesia, 17, 831-840.
13. Buijk S, Gyssens I, Mouton J, Verbrugh H, Touw D, Bruining H, (2001) Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Medicine, 27, 115-121.
14. Nicolau D, Crowe H, Nightingale C, Quintiliani R, (1995) Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. Journal of Antimicrobial Chemotherapy, 36, 395-401.
15. Koks C, Rosing H, Meenhorst P, Bult A, Beijnen J, (1995) High-performance liquid chromatographic determination of the antifungal drug fluconazole in plasma and saliva of human immunodeficiency virus-infected patients. Journal of Chromatography. B, Biomedical Applications, 663, 345-351.
16. Holford N, (1989) Wings for NONMEM. Available at: (accessed 7 July 2011).
17. Jonsson E, Karlsson M, (1999) Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Computer Methods and Programs in Biomedicine, 58, 51-64.
18. Cockcroft D, Gault M, (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31-41.
19. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO, (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. The AAPS Journal, 13, 143-151.
20. Lindbom L, Ribbing J, Jonsson EN, (2004) Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Computer Methods and Programs in Biomedicine, 75, 85-94.
21. R Development Core Team (2009) R: A language and environment for statistical computing. Available at: (accessed 7 July 2011).
22. Rousseau A, Léger F, Le Meur Y, Saint-Marcoux F, Paintaud G, Buchler M, Marquet P, (2004) Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Therapeutic Drug Monitoring, 26, 23-30.
23. Hooker A, Staatz C, Karlsson M, (2007) Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharmaceutical Research, 24, 2187-2197.
24. Hirata K, Aoyama T, Matsumoto Y, Ogawa F, Yamazaki H, Kikuti A, Yamamoto Y, (2007) Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi, 127, 897-901.
25. Hirata K, Matsumoto Y, Ohno K, Hirano M, Yamamoto Y, (2005) Pharmacokinetics of midazolam in critically ill patients receiving continuous hemodiafiltration using a polymethyl methacrylate and/or polysulfone membrane. Japanese Journal of Pharmaceutical Health Care and Science, 31, 99-104.
26. Sobue S, Sekiguchi K, Shimatani K, Tan K, (2004) Pharmacokinetics and safety of fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers. Journal of Clinical Pharmacology, 44, 284-292.
27. Sobue S, Tan K, Haug-Pihale G, (2005) The effects of hepatic impairment on the pharmacokinetics of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. British Journal of Clinical Pharmacology, 59, 160-166.
28. Csajka C, Décosterd L, Buclin T, Pagani J, Fattinger K, Bille J, Biollaz J, (2001) Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. European Journal of Clinical Pharmacology, 57, 723-727.
29. Rajagopalan P, Pelz R, Lipsett P, Swoboda S, Rinaldi M, Hendrix C, (2003) Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit. Pharmacotherapy, 23, 592-602.
30. Sobue S, Keith T, Cary L, Violette L, Angelika W, (2004) The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. British Journal of Clinical Pharmacology, 57, 773-784.
31. Pittrow L, Penk A, (1999) Special pharmacokinetics of fluconazole in septic, obese and burn patients. Mycoses, 42 (Suppl. 2), 87-90.
32. Berl T, Wilner K, Gardner M, Hansen R, Farmer B, Baris B, Henrich W, (1995) Pharmacokinetics of fluconazole in renal failure. Journal of the American Society of Nephrology, 6, 242-247.
33. Bergman S, Tyagi I, Ronald K, (2010) Antifungal dosing in critically ill patients. Current Fungal Infection Reports, 4, 78-86.